This is one of the most clinically useful posts I’ve read on “repurposed drugs in GBM”! You do the hard thing: you keep hope and epistemic honesty in the same frame.
A few physician-scientist notes I especially appreciate:
1. You start with the BBB reality check. In GBM, “promising in vitro” is almost meaningless until we ask: does enough drug reach the infiltrative margin behind a more intact barrier? That single constraint explains so much of the translational disappointment—and prevents patients from spending precious time chasing signal-free noise.
2. Valproate as a repeated “signal”, framed correctly. You acknowledge why it keeps resurfacing (HDAC / radiosensitization biology + clinical hints) without overselling it as a survival guarantee. That’s the right balance: plausible, testable, and best thought of as a layer during a defined window (e.g., around radiation), not a magic bullet.
3. Disulfiram / mebendazole / HCQ: strong stories, mixed human outcomes. The way you separate mechanism plausibility from trial reality is exactly how we should teach patients (and trainees) to think—especially when the internet is faster than evidence.
4. The “PPI caution” section is a quiet but high-impact clinical pearl. Supportive meds can inadvertently become tumor-relevant meds in a chemoradiation context; surfacing that nuance is one of the most patient-protective things you can do.
5. Your closing questions are gold. Shifting the conversation from “Should I add protocol X?” → “Does my tumor biology make me a candidate?” is how we keep agency while respecting complexity.
If you ever do a follow-up, I’d love a short “implementation” appendix: what you monitor when layering (LFTs/QT/drug–drug interactions, seizure threshold, steroid/glucose management, symptom goals), and what would make you stop a layer quickly. That kind of guardrail is what turns integrative care into responsible care.
I’m so grateful for clinicians like you who take the time to read closely, and for pulling out the exact points I hoped would help protect patients from noise. The implementation appendix request is spot on. I’ll plan a short practical add-on with monitoring, key interactions, and clear stop-rules for when to pull a layer quickly.
Thanks for the "just the facts" run down. I'm also hopeful that an existing or new PARP-Inhibitor could sensitize to Temodar or radiation therapy. I've been watching the conductor Michael Tilson-Thomas's struggle and wishing the best for him. I lost an uncle who was a musician to glioblastoma at a young age in the early 80s and I wish we had progressed further on this one. I know it's coming though (thank you dedicated researchers)!
I like that nothing here is oversold like you see so much on Substack. Nice work!
I think I’ll stick with my croissant.
: ) room for two?
Always. If you bring a cappuccino
This is one of the most clinically useful posts I’ve read on “repurposed drugs in GBM”! You do the hard thing: you keep hope and epistemic honesty in the same frame.
A few physician-scientist notes I especially appreciate:
1. You start with the BBB reality check. In GBM, “promising in vitro” is almost meaningless until we ask: does enough drug reach the infiltrative margin behind a more intact barrier? That single constraint explains so much of the translational disappointment—and prevents patients from spending precious time chasing signal-free noise.
2. Valproate as a repeated “signal”, framed correctly. You acknowledge why it keeps resurfacing (HDAC / radiosensitization biology + clinical hints) without overselling it as a survival guarantee. That’s the right balance: plausible, testable, and best thought of as a layer during a defined window (e.g., around radiation), not a magic bullet.
3. Disulfiram / mebendazole / HCQ: strong stories, mixed human outcomes. The way you separate mechanism plausibility from trial reality is exactly how we should teach patients (and trainees) to think—especially when the internet is faster than evidence.
4. The “PPI caution” section is a quiet but high-impact clinical pearl. Supportive meds can inadvertently become tumor-relevant meds in a chemoradiation context; surfacing that nuance is one of the most patient-protective things you can do.
5. Your closing questions are gold. Shifting the conversation from “Should I add protocol X?” → “Does my tumor biology make me a candidate?” is how we keep agency while respecting complexity.
If you ever do a follow-up, I’d love a short “implementation” appendix: what you monitor when layering (LFTs/QT/drug–drug interactions, seizure threshold, steroid/glucose management, symptom goals), and what would make you stop a layer quickly. That kind of guardrail is what turns integrative care into responsible care.
I’m so grateful for clinicians like you who take the time to read closely, and for pulling out the exact points I hoped would help protect patients from noise. The implementation appendix request is spot on. I’ll plan a short practical add-on with monitoring, key interactions, and clear stop-rules for when to pull a layer quickly.
Thanks for the "just the facts" run down. I'm also hopeful that an existing or new PARP-Inhibitor could sensitize to Temodar or radiation therapy. I've been watching the conductor Michael Tilson-Thomas's struggle and wishing the best for him. I lost an uncle who was a musician to glioblastoma at a young age in the early 80s and I wish we had progressed further on this one. I know it's coming though (thank you dedicated researchers)!
Great